* Clearside Biomedical announces first patient randomized in phase 2 clinical trial of cls-ta used together with eylea in patients with diabetic macular edema

* Clearside Biomedical Inc - currently expect to report three-month preliminary data in first half of 2018 Source text for Eikon: Further company coverage: